Mogamulizumab 是一种抗 C-C 趋化因子受体 4 抗体，越来越多地用于治疗 T 细胞恶性肿瘤，如皮肤 T 细胞淋巴瘤、成人 T 细胞白血病淋巴瘤和外周 T 细胞淋巴瘤。由于 CCR4 在恶性 T 细胞和调节性 T 细胞 (Treg) 上表达，因此 mogamulizumab 可能与免疫相关不良事件 (irAE) 增加相关。虽然有大量关于 mogamulizumab 相关皮疹 (MAR) 和移植物抗宿主病 (GVHD) 的文献，但其他报道的 irAE 尚未整理成一篇综述。这篇叙述性综述涵盖了 T 细胞患者中与 mogamulizumab 相关的 irAE淋巴瘤，重点关注 MAR 和 GVHD 以外的事件。我们在 PubMed 和 Google Scholar 中搜索了从开始到 2024 年 3 月发表的病例报告、病例系列、图表评论和临床试验。已确定的事件包括脱发、白癜风、关节炎、牛皮癣、心肌炎、肌炎/多发性肌炎、肝炎等。Mogamulizumab 的能力通过消除 Treg 来增强宿主免疫反应不仅增加了其疗效，而且对跨多个器官系统的自身免疫具有广泛的影响，类似于免疫检查点抑制剂疗法。尽管需要长期随访研究，但 irAE 的发生可能与总体临床反应的改善有关。

Mogamulizumab is an anti-C-C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review.This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others.Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed.